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Abstract
Background: Angiogenin (ANG) is a potent stimulator of angiogenesis. The aim of this study was to fabricate an
ANG-loaded scaffold and to evaluate its angiogenic and osteogenic effects. In this study, we fabricated an ANG-loaded
scaffold using bovine bone powder and fibrin glue. We then evaluated the structural, morphological, and mechanical
properties of the scaffold and the in vitro release profile of ANG. Cell proliferation, viability, and adhesion were
evaluated using endothelial cells in vitro, and angiogenesis and new bone formation were evaluated using a
rabbit calvarial defect model in vivo.
Results: Micro-computed tomography imaging showed that the bone powder was uniformly distributed in the
scaffold, and scanning electron microscopy showed that the bone powder was bridged by polymerized fibrin.
The porosity and compressive strength of the scaffolds were ~60 % and ~0.9 MPa, respectively, and were not
significantly altered by ANG loading. In vitro, at 7 days, approximately 0.4 μg and 1.3 μg of the ANG were released from
the FB/ANG 0.5 and FB/ANG 2.0, respectively and sustained slow release was observed until 25 days. The released ANG
stimulated cell proliferation and adherence and was not cytotoxic. Furthermore, in vivo implantation resulted in enhanced
angiogenesis, and new bone formation depended on the amount of loaded ANG.
Conclusions: These studies demonstrate that a fibrin and bone powder scaffold loaded with ANG might be useful to
promote bone regeneration by enhanced angiogenesis.
Keywords: Angiogenin, Fibrin, Scaffold, Bone regeneration, Angiogenesis
Background
Bone reconstruction requires bone graft surgery in various
conditions such as tumors, trauma, disease, and fracture of
the bone. Although small defects self-regenerate, large bone
defects remain challenging for bone replacement because
they do not heal themselves. To overcome these problems,
tissue engineering approaches have been applied to recon-
struct the bone. In tissue engineering, biomaterial scaffolds
are considered a crucial component because they provide a
physical environment for bone formation and play an
important role in cell growth, adhesion, and differentiation
[1]. When scaffolds are used for bone regeneration, they
often contain osteogenic growth factors or cytokines such
as bone morphogenetic protein-2 (BMP-2) to enhance
bone repair [2].
In addition to osteogenic stimulation, angiogenesis has
recently been the focus of efforts to improve the clinical
success of bone tissue repair. Angiogenesis is a key event
in bone repair because new blood vessels serve as a
route for providing oxygen, nutrients, and migration of
bone precursor cells to the injury site [3]. Therefore, in
bone tissue engineering, several studies have applied
angiogenic growth factors such as vascular endothelial
growth factor (VEGF) [4] and fibroblast growth factor
(FGF) [5] to increase angiogenesis for bone repair.
Angiogenin (ANG) is a potent growth factor that can
stimulate new blood vessel formation. ANG is a normal
constituent of circulating blood with angiogenic activity
[6]. It has also been found to be involved in neovascular-
ization induced by various other angiogenic proteins
such as FGF and VEGF [7].
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Allogeneic mineralized bone powder has been widely
used in the clinic to reconstruct bone defects because the
molecular structure of bone is the same across species,
making it possible to use bone from animal sources for
bone grafts to enhance bone healing efficiency [8]. Several
polymers such as a collagen [9], gelatin [10], chitosan [11],
and fibrin [12] are used to fabricate porous scaffolds using
bone powder. In particular, polymerized fibrin fibrous struc-
tures provide a temporary matrix during the rebuilding and
repair of tissues [13]. Some studies have demonstrated that
composite biomaterials and fibrin glue exhibit biocompati-
bility and increased osteoconductivity when compared to
the biomaterials applied alone [14, 15]. Furthermore, fibrin
has also been used as a delivery system because it serves as
a binding reservoir for several growth factors, and the
growth factors contained in fibrin gels are released in a
delayed manner because the gel slows their diffusion [16].
Therefore, in this study, we fabricated an ANG-
containing porous scaffold using fibrin glue and bovine
bone powder. The microstructural and mechanical prop-
erties of the scaffold and the release pattern of ANG
were characterized. The biocompatibility of the scaffold
was evaluated using human umbilical vein cells (HUVECs)
in vitro, and the tissue response and ability to induce
angiogenesis and bone formation in vivo were evaluated
using a rabbit calvarial defect model.
Methods
Scaffold preparation
In the present study, calcium phosphate–coated bovine
bone powder (Biocera®; Oscotec, Chunan, Korea) was
used as the bone powder material, and fibrin glue from a
Greenplast kit was used (Greenplast kit; Green Cross
Corp., Seoul, Korea). To construct the scaffolds, 30 mg
of bone powder was placed in each hexahedron-shaped
hole of a mold (8 mm × 8 mm× 1.5 mm). Next, 0.2 mL
of fibrinogen solution (40 mg/mL in PBS) was prepared.
Recombinant human ANG (rhANG; MybioSource, San
Diego, CA) (0.5 μg or 2.0 μg) was then added into the
fibrinogen solution to prepare the ANG-containing scaf-
fold. Then, the fibrinogen or fibrinogen/ANG solution
was added to the bone powder and mixed well. Throm-
bin (Greenplast Kit; 5 U/mL) solution (0.1 mL) was
added, and the composites were rapidly blended. The
resulting polymerized mixture was freeze-dried for 3 days
to obtain a fibrin/bone powder (FB) scaffold.
Micro-computerized tomography analysis
To evaluate the entire scaffold structure, samples were
scanned with an aluminum filter using micro-computerized
tomography (Micro-CT; Sky-Scan 1172TM; Skyscan,
Kontich, Belgium). Three-dimensional and trans-sectional
images were obtained from reconstructed scanned data
set using CT-analyzer software (Skyscan).
Microstructural analysis
To observe the structure of the scaffold, fabricated scaffolds
were sputter-coated with gold for 120 s under vacuum.
Then, the scaffolds were observed using a scanning electron
microscope (SEM; EM-30; Coxem, Daejeon, Korea).
Porosity and compressive strength analysis
Porosity was measured using a mercury intrusion poro-
simeter (AutoPore IV9500, Oak Ridge, TN). Briefly, scaf-
folds were sealed in a penetrometer, weighed, and
subjected to analysis [17]. To evaluate the mechanical
properties of the scaffold, compressive strength was ana-
lyzed. The fabricated scaffolds were subjected to a com-
pression test using an Instron model 4505 universal test
machine (Instron, Canton, MA) by applying a load via a
1 N load cell at a crosshead speed of 0.5 mm/min under
ambient conditions.
Determination of ANG release from scaffolds in vitro
The kinetics of ANG release from the FB/ANG scaffold
were determined. The fabricated scaffolds were immersed
in 2 mL of phosphate-buffered saline (PBS, pH 7.4). The
samples were incubated at 37 °C under continuous agita-
tion. At various time points, the supernatant was collected
and fresh buffer was replenished. The quantitative deter-
mination of ANG was performed using an enzyme-linked
immunosorbent assay (ELISA) kit (R&D Systems, Minne-
apolis, MN). Then, the cumulative release of ANG was
calculated and represented as a percentage of the total
amount of ANG in the scaffold.
Cell culture
To evaluate the biocompatibility of the scaffold, im-
mortalized HUVECs (EA.Hy926) were purchased from
American Type Culture Collection (ATCC, Manassas,
VA). The cells were cultured in DMEM (Gibco-BRL,
Gaithersburg, MD) containing 10 % fetal bovine serum
(FBS) and 1 % antibiotics at 37 °C under 5 % CO2 and
100 % humidity.
Cell proliferation assay and evaluation of cytotoxicity
CellTiter96® Aqueous One solution (Promega, Madison,
Wi) was used to measure cell proliferation. The EA.Hy926
cells were seeded and cultured on the FB and FB/ANG
scaffolds. At predetermined time points (1, 5, 10, or
15 days), 200 μL of MTS reagent was mixed with 500 μL
of culture media and added to each well. After incubation
for 2 h, the supernatant was taken, and its absorbance was
measured at 490 nm using an ELISA reader (SpectraMAX
M3; Molecular Devices, Sunnyvale, CA). In addition, the
cytotoxicity of the fabricated scaffold was evaluated using
a Live/Dead® Viability/Cytotoxicity staining kit (Molecular
Probe, Eugene, OR). After 3 days of cultivation, the speci-
men was rinsed with PBS to remove the phenol red, and
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reagent solution was added. After incubation for 30 min
in a CO2 incubator, the samples were observed using an
inverted fluorescence microscope (DM IL LED Fluo; Leica
Microsystems, Wetzlar, Germany).
Cell adhesion observation
SEM was used to observe cell adhesion to the scaffolds.
After 5 days of culture, the samples were fixed with
2.5 % glutaraldehyde, and post-fixation was performed
with 0.1 % osmium tetroxide (OsO4; Sigma). The sample
was then dehydrated with a graded ethanol series (50 %,
75 %, 95 %, 100 %, and 100 %). The samples were then
sputter-coated with gold and observed by SEM (EM-30;
Coxem).
Animal experiments
All animal experiments were performed according to the
guidelines of the Wonkwang University Institutional
Animal Care and Use Committee (Wonkwang University
IACUC; WKU11-31). In this study, 3-month-old New
Zealand white rabbits weighing 2.5–3.0 kg were used.
To generate calvarial defects, the rabbits were anesthe-
tized, the calvarium was exposed through a skin incision,
and circular calvarial defects were made using a trephine
bur (8 mm diameter) [18]. The FB and FB/ANG scaf-
folds were then implanted in the induced calvarial defects.
After 1, 2, 4, and 8 weeks, the animals were sacrificed, and
the bone defect regions were dissected out from the host
bone. The extracted bone tissue was then fixed with 4 %
paraformaldehyde buffered with 0.1 M phosphate (pH 7.2)
for 5 days before further experiments.
Micro-computed tomography
To analyze the newly formed bone, the bone specimens
were scanned using a micro-CT system (Sky-Scan 1172TM;
Skyscan, Kontich, Belgium) at 60 kV and 167 μA. Then, the
image data were reconstructed using CT-analyzer software
(Skyscan), and a three-dimensional image was recon-
structed. A cylindrical region of interest (ROI) was
positioned over the defect site. The volume of the
newly formed bone was measured by assigning a thresh-
old, and the percentage of the bone volume (% BV) was
calculated by dividing the volume of the newly formed
bone by the total volume within the ROI.
Histology
After micro-CT scanning, the samples were dehydrated
in a graded alcohol series (80–100 %), decalcified in 8 %
formic acid/8 % HCl, and embedded in paraffin. Sections
with a thickness of 5 μm were prepared from the sam-
ples and mounted on slides, and the samples were then
stained with hematoxylin-eosin and Goldner’s Masson
trichrome (MT) stain.
Statistical analysis
All experiments were performed in triplicate, and statis-
tical analyses were performed using GraphPad Prism
statistical analysis software (GraphPad Software, San
Diego, CA). Significant differences among groups were
identified by ANOVA followed by t-test. Values in the
text are expressed as the means ± standard deviation
(SD), and P < 0.05 was considered statistically significant.
Results
Structural characterization of FB and FB/ANG scaffolds
In this study, we successfully fabricated ANG-containing
porous scaffolds using fibrin glue and bovine bone powder.
Micro-CT imaging showed that the bovine bone powder
was uniformly distributed in the FB, FB/ANG 0.5, and FB/
ANG 2.0 scaffolds. In addition, trans-sectional micro-CT
images indicated that numerous pores were present in all
scaffolds (Fig. 1). SEM imaging of the fabricated scaffolds
showed that the fibrin glue formed fibrin layers that
branched among the bone powder particles. In addition,
high-magnification observation showed that the fibrin
layers consisted of a large number of micro-pores because
of the formation of fibrin networks (Fig. 2a).
Measurement of porosity and compressive strength
In bone tissue engineering, the porosity of the scaffold is
important for angiogenesis, cell migration, and nutrient
supplementation [19, 20]. Therefore, we assessed the
porosity of the fabricated scaffolds. The porosity values
of the FB, FB/ANG 0.5, and FB/ANG 2.0 scaffolds were
61.94 % ± 0.52 %, 61.61 % ± 0.73 %, and 61.56 % ± 1.07 %,
respectively, which were not significantly different from
each other (Fig. 2b). These results demonstrate that the
porosity of the scaffold is not influenced by the addition
of ANG. In addition, we measured the compressive
strength of the scaffold because the mechanical
Fig. 1 Representative micro-computed tomography images. Three-
dimensional (upper panel) and trans-sectional images (lower
panel) of fibrin glue/bone powder scaffold (FB), FB loaded with
0.5 μg of angiogenin (ANG) (FB/ANG 0.5), and FB loaded with 2.0 μg
of ANG (FB/ANG 2.0) from micro-computed tomography (micro-CT)
analysis. Scale bar = 2 mm
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properties are also important for bone reconstruction.
The compressive strength values of the FB, FB/ANG 0.5,
and FB/ANG 2.0 scaffolds were 0.94 ± 0.06 MPa, 0.95 ±
0.04 MPa, and 0.97 % ± 0.01 %, respectively, which were
also not significantly different from each other (Fig. 2c).
Release kinetics of ANG
To evaluate ANG release kinetics from the scaffolds, ANG
release over time was determined by ELISA (Fig. 3). Until
the 7 days, fast release pattern were observed both of FB/
ANG 0.5 and FB/ANG 2.0 scaffolds. Especially, at 7 days,
approximately 0.4 μg and 1.3 μg of the ANG were released
from the FB/ANG 0.5 and FB/ANG 2.0, respectively. And
the slow release was sustained from 8 days to 25 days.
Biocompatibility
The effects of the addition of ANG on cell proliferation,
cytotoxicity, and cell adhesion were evaluated. At day 1
of culture, the proliferation of cells cultured on the
scaffolds was not significantly different among scaffold
groups. However, with increased culture time, prolifera-
tion was significantly increased in cells cultured on the
FB/ANG scaffold. In addition, the proliferation of cells
on the FB/ANG 2.0 scaffold was significantly higher than
that of cells on the FB/ANG 0.5 scaffold (Fig. 4a). Live/
dead fluorescence imaging showed that most cells were
viable on all scaffolds. Furthermore, the density of live
green cells was consistent with the results of the MTS
assay (Fig. 4b). To determine whether cells could attach
to the scaffold, cells were cultured and their morphology
Fig. 2 Characterization of fibrin glue/bone powder scaffold. Scanning electron microscopy (SEM) showed that the polymerized fibrin formed a layer and
branched among the bone powder particles. In addition, the fibrin layer contained numerous micron-sized pores (a). The porosity (b) and compressive
strength (c) were not affected by ANG loading in the scaffold
Fig. 3 In vitro cumulative release of angiogenin (ANG) from scaffolds.
The values represent the mean ± standard deviation (SD). At 7 days,
approximately 0.4 μg and 1.3 μg of the ANG were released from the
FB/ANG 0.5 and FB/ANG 2.0, respectively. Then the sustained slow
release was observed until 25 days. The data shown are the mean ± SD
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observed by SEM after 5 days of culturing. SEM imaging
showed that cells adhered and grew on the scaffolds.
Attached cells were rarely observed on the FB scaffold but
were more frequently observed on scaffolds constructed
with increasing ANG concentrations (Fig. 4c). These results
are also consistent with the findings of our MTS assay.
In vivo analysis of neovascularization and new bone
formation
To determine the effects of ANG-containing FB scaf-
folds on bone regeneration, we implanted the scaffolds
in critical-sized defects in rabbits. At 2 weeks post-
implantation, more blood vessels supplying connective
tissue were clearly observed in the FB/ANG groups than
in the FB scaffold group, and the number of blood
vessels increased as the ANG concentration increased
(Fig. 5). When characterizing bone regeneration at
8 weeks, new bone formation was observed around the
margin of the defect site in the group with untreated de-
fects. In contrast, new bone formation was observed not
only around margin of the defective site but also around
the bone powder in the defective site in the groups
Fig. 4 In vitro cellular biocompatibility of the scaffold. The biocompartibility was evaluated using an immortalized human umbilical vein cell line
(EA.Hy926). Cells were cultured on each scaffold and proliferated gradually over time on all scaffolds. However, the proliferation was the highest
on the FB scaffold loaded with 2 μg of ANG (FB/ANG 2.0) (a). After 3 days of cultivation, live/dead staining showed that most of the cells were
viable (stained green by Calcein AM), whereas dead cells (stained red by EthD-1) were not observed. Scale bar = 500 μm (b). To evaluate cell adhesion,
scanning electron microscopy (SEM) (C) was performed after 5 days of cultivation. SEM images showed that cell adhesion increased as ANG
content increased (c). The data shown are the mean ± SD of three independent experiments. * and # indicate significantly different when
compared with the FB scaffold and FB/ANG 0.5 scaffold, respectively
Fig. 5 Hematoxylin-eosin-stained image of blood vessel formation in the central area of the calvarial defect site at 2 weeks after implantation. Many
blood vessels clearly penetrated into the connective tissue and near the new bone in the FB/ANG 2.0 group. In addition, multinuclear cells and fibroblasts
infiltrated into the connective tissue. Asterisk: residual material bone powder, black arrow: blood vessels. Empty: non-treated defect, FB: fibrin glue/bone
scaffold alone, FB/ANG 0.5; FB scaffold loaded with 0.5 μg of ANG, FB/ANG 2.0; FB scaffold loaded with 2.0 μg of ANG. Scale bar = 250 μm
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implanted with FB and FB/ANG scaffolds. Extensive newly
formed bone was observed in the FB/ANG groups, and the
bone had coalesced with the host bone. Furthermore, ex-
tensive new bone was observed in the group implanted
with FB/ANG 2.0 scaffolds (Fig. 6). Images of the central
area of the calvarial defects collected after MT staining
showed large amounts of fibroblastic connective tissue in
the group with untreated defects, whereas mature new
bone was clearly observed in the FB and FB/ANG groups.
In addition, more newly formed bone was observed in
the FB/ANG 2.0 group than in the FB/ANG 0.5 group
(Fig. 7).
Micro-computed tomography evaluation
Reconstructed three-dimensional micro-CT images of
non-implanted (empty) and implanted FB, FB/ANG 0.5,
and FB/ANG 2.0 scaffolds are shown in Fig. 8a. In all
groups, bone regeneration occurred from the margins of
the defect site. In particular, new bone was generated
not only in the margin of the defect but also in the
central area of the defect among the bone powder in the
bone powder-containing scaffolds (FB, FB/ANG 0.5, and
FB/ANG 2.0). Quantification of bone regeneration re-
vealed significant differences in the group with untreated
defects and the groups implanted with FB and FB/ANG
scaffolds. In particular, at 8 weeks, the newly formed
bone volume was significantly higher in the FB/ANG 2.0
implanted group (34.67 % ± 1.25 %) than in the un-
treated defect (12.82 % ± 1.49 %), FB (20.12 % ± 1.08 %),
and FB/ANG 0.5 (27.34 % ± 2.17 %) groups (Fig. 8b).
The results of the micro-CT analysis were similar to
those of the histological analysis.
Discussion
Bone tissue engineering is promising for treating large
bone defects in patients with severe bone loss. There-
fore, many studies have attempted to improve bone
tissue defect repair using biological scaffolds. One of the
major factors in bone tissue engineering is angiogenesis
Fig. 6 Microscopic evaluation of calvarial sections stained with
hematoxylin-eosin after 8 weeks. Remaining bone particle material
(asterisk) was observed in all scaffold-implanted groups. Newly generated
mineralized bone (black arrow) was observed near the margin of
the defect site (arrowhead) in the calvarial bone. HB represents the
host bone. Scale bar = 500 μm
Fig. 7 Goldner’s Masson trichrome staining of regenerated bone in
the central area of the calvarial defect after implantation for 4 weeks
and 8 weeks. After implantation for 4 weeks, mature bone (arrow)
was distinctly observed around the residual material bone particles
in the angiogenin-containing groups. Chronic inflammatory cells
were also observed to infiltrate all defect areas. After implantation
for 8 weeks, the greatest extent of regenerated bone (arrow) and
blood vessels (arrowhead) was observed in the FB/ANG 2.0 group.
Asterisk: residual material bone particles. Scale bar = 250 μm
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[3]. Therefore, in scaffold design, porous structure is im-
portant because porosity enables cell infiltration, nutri-
ent inflow, and vascular ingrowth [20]. Furthermore,
current strategies for bone tissue regeneration focus on
the combination of scaffolds and growth factors with
osteoinductive and angiogenic potential to promote bone
ingrowth [21]. Various studies have reported scaffold sys-
tems fabricated to deliver angiogenic growth factors such
as VEGF and FGF [22, 23]. However, the application of
ANG-containing scaffolds has not yet been evaluated in
bone tissue engineering.
In this study, we attempted to prepare ANG-containing
FB scaffolds for the first time, and vascularization and
bone regeneration capacity were evaluated. Fibrinogen
(40 mg/mL) and thrombin (5 U/mL) were used to prepare
the scaffolds because these concentrations were optimized
in pilot experiments [24]. Micro-CT imaging (Fig. 1)
showed that the scaffolds were successfully fabricated
with a uniform distribution of bone powder. Further-
more, SEM showed that the polymerized fibrin formed
layers bound to the bone powder granules, resulting in
the construction of a three-dimensional scaffold. When
scaffolds are prepared using fibrin glue, their stiffness
is influenced by the type and content of protein added,
and the mechanical strength of fibrin matrix was
shown to be increased by composition with collagen
protein [25]. However, in the present study, there were
no significant differences between FB scaffolds and FB/
ANG scaffolds with regard to porosity and mechanical
strength. These results suggest that ANG does not
affect the porosity and mechanical properties of the FB
scaffold, probably because of the low protein content
and the nature of the protein, which may not affect the
fibrin network.
During bone regeneration, angiogenesis precedes osteo-
genesis. Therefore, several studies have attempted the
fabrication of angiogenic growth factor-releasing scaffolds
[6, 7]. For instance, Leach et al. fabricated an angiogenic
growth factor (VEGF)-coated scaffold and showed that it
induced angiogenesis and accelerated bone healing in rat
bone defects [26]. The VEGF release profile showed an
initial rapid burst release pattern within approximately
5 days. Jeon et al. showed that the release profile of loaded
FGF growth factor was influenced by the fibrinogen and
thrombin concentration in a fibrin-based scaffold [27];
when the fibrin gel was prepared using fibrinogen at
94.3 mg/mL and thrombin at 33.3 U/mL, 60 % of the
growth factor was released in the first 3 days. In contrast,
our results showed that the initial burst release occurred
in the first 7 days, with approximately 60 % of the ANG
released, followed by a slow release profile that was
sustained until 25 days. The different release profiles
observed may be the result of different concentrations
of fibrinogen and thrombin [27] and also differences in
parameters such as morphological properties, material
components, and preparation method [16].
In vitro cell culture is the starting point to evaluate the
biocompatibility of developed scaffolds. In this study, cell
proliferation and cytotoxicity were determined to evalu-
ate biocompatibility. Several studies have reported that
ANG stimulates endothelial cell proliferation and angio-
genesis [7, 28]. In the present study, the MTS and cyto-
toxicity assays showed that FB/ANG enhanced cell
proliferation and was not cytotoxic. Furthermore, cell
adhesion was analyzed in SEM images (Fig. 4c), which
showed that a higher amount of cells grew and adhered
on FB/ANG scaffolds than on FB scaffolds. These results
indicate that cell adhesion was also enhanced by addition
Fig. 8 Three dimensional images of calvarial defects after implantation for 8 weeks (a). Newly regenerated bone covered the entire defect with
scaffold treatment after implantation for 8 weeks. a; empty, b; FB, c; FB/ANG 0.5, d; FB/ANG 2.0. B. The % bone volume generated in the bone
defects. The amount of new bone significantly increased over the study duration in the FB/ANG-implanted groups (b). Furthermore, the FB/ANG
2.0 group showed higher new bone formation than the FB/ANG 0.5 group. Each column value represents the mean ± SD. * and # indicate significantly
different when compared with empty and FB scaffold groups, respectively (n = 4, *, #P < 0.05 and **, ##P < 0.01)
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of ANG to the scaffold because ANG supports the adhe-
sion of endothelial cells [29].
Our in vitro results suggest that FB/ANG scaffolds
could enable bone formation through enhanced angio-
genesis. Therefore, in this study, we examined whether
ANG-containing FB scaffolds could improve new bone
formation using an in vivo rabbit calvarial defect model,
which has been widely used to evaluate the performance
of scaffolds in bone regeneration.
In bone tissue engineering, several growth factors
(e.g., VEGF, FGF2, and PDGF) have been used to
provide increased vascularization because new vessels
support bone regeneration [3]. Comez et al. [23] re-
ported enhanced bone healing in rat calvarial bone
defects using FGF2 and a poly-L/D-lactide scaffold.
Kaigler et al. reported enhanced bone regeneration
using VEGF and poly (L/D-lactide and glycolide) scaffolds
in irradiated rat osseous defects [30]. These previous
studies indicate that angiogenic growth factors not
only increase angiogenesis but also improve bone
regeneration.
Given the pivotal role of ANG in angiogenesis, several
studies have reported that neovascularization induced by
ANG may enhance the healing of tissues such as the
liver [31] and meniscus [32]. In addition, a previous study
attempted the application of ANG with a collagen-chitosan
scaffold for skin tissue engineering [33]. These previous re-
ports suggest that ANG also can be used as a potential an-
giogenic growth factor in bone tissue engineering. In our
in vivo study, the number of new blood vessels was signifi-
cantly increased at 2 weeks in the group implanted with
ANG-containing scaffolds. Furthermore, the regenerated
bone volume was also significantly increased by ANG
treatment. Although the exact mechanism was not eval-
uated in this study, these results suggest that induced
vascularization by scaffold-released ANG improved new
bone regeneration.
Conclusions
In summary, we prepared an ANG-containing FB scaffold.
The scaffold not only provided a suitable environment for
the adhesion and proliferation of endothelial cells but also
increased cell proliferation and adhesion. Furthermore,
ANG-containing scaffolds promoted vascularization and
improved new bone regeneration in calvarial defects
in vivo. This study highlights the potential of using ANG-
containing FB scaffolds for bone tissue engineering appli-
cations. However, further studies of the exact mechanism
of angiogenesis and osteogenesis induced by FB/ANG are
warranted.
Availability of supporting data
The data sets supporting the results of this article are
inclued within the article.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BSK conducted the experiment and drafted the manuscript. KJS performed
the in vivo experiment and analyzed. SSY helped to conduct the experiment.
HWK and HJL participated in the design of the study. JL conceived in the
design of experiments and help to draft the manuscript. All authors read and
approved the final manuscript.
Acknowledgement
This research was supported by Basic Science Research Program through the
National Research Foundation of Korea (NRF) funded by the Ministry of Science,
ICT and future Planning (NRF-2015R1A2A2A01004888).
Author details
1Wonkwang Bone Regeneration Research Institute, Wonkwang University,
Iksan 570-749, Korea. 2Bonecell Biotech Inc., Dunsan-dong, Seo-gu, Daejeon
302-830, Korea. 3Department of Herbal Crop Research, NIHHS, RDA,
Eumseong 369-873, Korea. 4Department of Dentistry, Oral and Maxillofacial,
Wonkwang University, Iksan 570-749, Korea.
Received: 22 July 2015 Accepted: 4 August 2015
References
1. Kuboki Y, Jin Q, Takita H. Geometry of carriers controlling phenotypic
expression in BMP-induced osteogenesis and chondrogenesis. J Bone Joint
Surg Am. 2001;83-A Suppl 1:S105–15.
2. Murata M, Sato D, Hino J, Akazawa T, Tazaki J, Ito K, et al. Acid-insoluble
human dentin as carrier material for recombinant human BMP-2. J Biomed
Mater Res A. 2012;100:571–7.
3. Hankenson KD, Dishowitz M, Gray C, Schenker M. Angiogenesis in bone
regeneration. Injury. 2011;42:556–61.
4. Ozturk BY, Inci I, Egri S, Ozturk AM, Yetkin H, Goktas G, et al. The treatment
of segmental bone defects in rabbit tibiae with vascular endothelial growth
factor (VEGF)-loaded gelatin/hydroxyapatite "cryogel" scaffold. J Pediatr
Orthop B. 2013;23:767–74.
5. Devescovi V, Leonardi E, Ciapetti G, Cenni E. Growth factors in bone repair.
Chir Organi Mov. 2008;92:161–8.
6. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, et al.
Isolation and characterization of angiogenin, an angiogenic protein from
human carcinoma cells. Biochemistry (Mosc). 1985;24:5480–6.
7. Kishimoto K, Liu S, Tsuji T, Olson KA, Hu GF. Endogenous angiogenin in
endothelial cells is a general requirement for cell proliferation and
angiogenesis. Oncogene. 2005;24:445–56.
8. Hatano N, Shimizu Y, Ooya K. A clinical long-term radiographic evaluation of
graft height changes after maxillary sinus floor augmentation with a 2:1
autogenous bone/xenograft mixture and simultaneous placement of dental
implants. Clin Oral Implants Res. 2004;15:339–45.
9. Yao PP, Sung CY. Securinine metabolism. Zhonghua yi xue za zhi.
1973;4:229–35.
10. Thevis M, Sigmund G, Gougoulidis V, Beuck S, Schlorer N, Thomas A, et al.
Screening for benfluorex and its major urinary metabolites in routine
doping controls. Anal Bioanal Chem. 2011;401:543–51.
11. Portha B, Serradas P, Bailbe D, Blondel O, Picarel F. Effect of benfluorex on
insulin secretion and insulin action in streptozotocin-diabetic rats. Diabetes
Metab Rev. 1993;9 Suppl 1:57S–63.
12. IIa B. Pharmacology of alkaloid securinine. Farmakol Toksikol. 1956;19:3–5.
13. Clark RA, Lanigan JM, DellaPelle P, Manseau E, Dvorak HF, Colvin RB.
Fibronectin and fibrin provide a provisional matrix for epidermal cell migration
during wound reepithelialization. J Invest Dermatol. 1982;79:264–9.
14. Boudes A, Lavoute C, Avierinos JF, Le Dolley Y, Villacampa C, Salem A, et al.
Valvular heart disease associated with benfluorex therapy: high prevalence
in patients with unexplained restrictive valvular heart disease. Eur J
Echocardiogr. 2011;12:688–95.
15. Bondon-Guitton E, Prevot G, Didier A, Montastruc JL. Pulmonary arterial
hypertension and benfluorex: 5 case reports. Therapie. 2011;66:135–8.
16. Breen A, O'Brien T, Pandit A. Fibrin as a delivery system for therapeutic
drugs and biomolecules. Tissue Eng Part B. 2009;15:201–14.
Kim et al. Biomaterials Research  (2015) 19:18 Page 8 of 9
17. Borden M, El-Amin SF, Attawia M, Laurencin CT. Structural and human
cellular assessment of a novel microsphere-based tissue engineered scaffold
for bone repair. Biomaterials. 2003;24:597–609.
18. Stephan SJ, Tholpady SS, Gross B, Petrie-Aronin CE, Botchway EA, Nair LS,
et al. Injectable tissue-engineered bone repair of a rat calvarial defect.
Laryngoscope. 2010;120:895–901.
19. Hing KA. Bone repair in the twenty-first century: biology, chemistry or
engineering? Philos Transact A Math Phys Eng Sci. 2004;362:2821–50.
20. Karageorgiou V, Kaplan D. Porosity of 3D biomaterial scaffolds and
osteogenesis. Biomaterials. 2005;26:5474–91.
21. Su J, Xu H, Sun J, Gong X, Zhao H. Dual Delivery of BMP-2 and bFGF from a
New Nano-Composite Scaffold, Loaded with Vascular Stents for Large-Size
Mandibular Defect Regeneration. Int J Mol Sci. 2013;14:12714–28.
22. Luo T, Zhang W, Shi B, Cheng X, Zhang Y. Enhanced bone regeneration
around dental implant with bone morphogenetic protein 2 gene and
vascular endothelial growth factor protein delivery. Clin Oral Implants Res.
2012;23:467–73.
23. Gomez G, Korkiakoski S, Gonzalez MM, Lansman S, Ella V, Salo T, et al. Effect
of FGF and polylactide scaffolds on calvarial bone healing with growth factor
on biodegradable polymer scaffolds. J Craniofac Surg. 2006;17:935–42.
24. Kim BS, Sung HM, You HK, Lee J. Effects of fibrinogen concentration on
fibrin glue and bone powder scaffolds in bone regeneration. J Biosci
Bioeng. 2014;118:469–75.
25. Rowe SL, Stegemann JP. Interpenetrating collagen-fibrin composite
matrices with varying protein contents and ratios. Biomacromolecules.
2006;7:2942–8.
26. Leach JK, Kaigler D, Wang Z, Krebsbach PH, Mooney DJ. Coating of
VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone
regeneration. Biomaterials. 2006;27:3249–55.
27. Jeon O, Ryu SH, Chung JH, Kim BS. Control of basic fibroblast growth factor
release from fibrin gel with heparin and concentrations of fibrinogen and
thrombin. J Control Release. 2005;105:249–59.
28. Liu S, Yu D, Xu ZP, Riordan JF, Hu GF. Angiogenin activates Erk1/2 in human
umbilical vein endothelial cells. Biochem Biophys Res Commun.
2001;287:305–10.
29. Soncin F. Angiogenin supports endothelial and fibroblast cell adhesion.
Proc Natl Acad Sci U S A. 1992;89:2232–6.
30. Kaigler D, Wang Z, Horger K, Mooney DJ, Krebsbach PH. VEGF scaffolds
enhance angiogenesis and bone regeneration in irradiated osseous defects.
J Bone Miner Res. 2006;21:735–44.
31. [Peculiarities of hepatic experimental wound healing in rats treated with
angiogenin]. Morfologiia. 2005;128:98–100.
32. King TV, Vallee BL. Neovascularisation of the meniscus with angiogenin.
An experimental study in rabbits. J Bone Joint Surg Br. 1991;73:587–90.
33. Shi H, Han C, Mao Z, Ma L, Gao C. Enhanced angiogenesis in porous
collagen-chitosan scaffolds loaded with angiogenin. Tissue Eng Part A.
2008;14:1775–85.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kim et al. Biomaterials Research  (2015) 19:18 Page 9 of 9
